• Publications
  • Influence
The epidemiology of Parkinson's disease: risk factors and prevention
Since 2006, several longitudinal studies have assessed environmental or behavioural factors that seem to modify the risk of developing Parkinson's disease. Increased risk of Parkinson's disease hasExpand
  • 525
  • 34
Neuroprotection by Caffeine and A2A Adenosine Receptor Inactivation in a Model of Parkinson's Disease
Recent epidemiological studies have established an association between the common consumption of coffee or other caffeinated beverages and a reduced risk of developing Parkinson's disease (PD). ToExpand
  • 501
  • 29
  • PDF
Molecular markers of early Parkinson's disease based on gene expression in blood
Parkinson's disease (PD) progresses relentlessly and affects five million people worldwide. Laboratory tests for PD are critically needed for developing treatments designed to slow or preventExpand
  • 423
  • 23
  • PDF
A2A Adenosine Receptor Deficiency Attenuates Brain Injury Induced by Transient Focal Ischemia in Mice
Extracellular adenosine critically modulates ischemic brain injury, at least in part through activation of the A1 adenosine receptor. However, the role played by the A2A receptor has been obscured byExpand
  • 522
  • 21
  • PDF
Adenosine inhibits IL‐12 and TNF‐α production via adenosine A2a receptor‐dependent and independent mechanisms
Interleukin 12 (IL‐12) is a crucial cytokine in the regulation of T helper 1 vs. T helper 2 immune responses. In the present study, we investigated the effect of the endogenous purine nucleosideExpand
  • 476
  • 18
Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32.
Interactions between dopaminergic and glutamatergic systems in the striatum are thought to underlie both the symptoms and adverse effects of treatment of Parkinson's disease. We have previouslyExpand
  • 168
  • 18
  • PDF
Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease
We investigated whether nonsteroidal antiinflammatory drug use was associated with a lower risk for Parkinson's disease (PD) in a large cohort of US men and women. PD risk was lower among ibuprofenExpand
  • 411
  • 15
Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease.
In the pursuit of improved treatments for Parkinson's disease (PD), the adenosine A(2A) receptor has emerged as an attractive nondopaminergic target. Based on the compelling behavioral pharmacologyExpand
  • 217
  • 13
The role of the D2 dopamine receptor (D2R) in A2A adenosine receptor (A2AR)-mediated behavioral and cellular responses as revealed by A2A and D2 receptor knockout mice
The A2AR is largely coexpressed with D2Rs and enkephalin mRNA in the striatum where it modulates dopaminergic activity. Activation of the A2AR antagonizes D2R-mediated behavioral and neurochemicalExpand
  • 236
  • 12
Acute regulation of tyrosine hydroxylase by nerve activity and by neurotransmitters via phosphorylation.
Although stimulation of adrenergic nerves or adrenal chromaffin cells causes the release of catecholamines, in many cases it does not cause a decrease in the catecholamine content of these cells. OneExpand
  • 501
  • 11